Life sciences software vendor Medidata is collaborating with US-based Moderna on clinical trials of its Covid-19 vaccine, mRNA-1273.

Moderna is planning to launch its Phase III trial of mRNA-1273 in 30,000 patients this month. The company will leverage Medidata’s suite of Rave technology to support virtualisation of the trial to speed up data capture and reduce the need for burdensome patient site visits.

Medidata co-founder and co-CEO Tarek Sherif said: “We are proud to be working with Moderna on these breakthrough trials, which are so important to medical science and the health of our global society.

“The extensive partnership we’ve built together over many years is allowing us to support these critical clinical studies. Clearly, the faster we can arrive at answers, the better it will be for everyone, everywhere.”

Moderna chief digital and operational excellence officer Marcello Damiani added: “We are pleased to collaborate with Medidata.

“Medidata’s unified platform is helping us put participants at the centre of our efforts to develop a safe and effective vaccine against Covid-19.”